APA (7th ed.) Citation

VD, T., DD, A., VH, H., N, V. T., TC, T., J, M., . . . D, W. (2025). Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial. Vaccine, 44, 126542. https://doi.org/10.1016/j.vaccine.2024.126542

Chicago Style (17th ed.) Citation

VD, Thiem, et al. "Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: A Randomised, Comparator-controlled, Phase 2 Trial." Vaccine 44 (2025): 126542. https://doi.org/10.1016/j.vaccine.2024.126542.

MLA (9th ed.) Citation

VD, Thiem, et al. "Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: A Randomised, Comparator-controlled, Phase 2 Trial." Vaccine, vol. 44, 2025, p. 126542, https://doi.org/10.1016/j.vaccine.2024.126542.